[
  {
    "trial": "T036",
    "source": "fulltext",
    "arms": {
      "K1 group": {
        "randomized": "26",
        "analysed": "26"
      },
      "K2 group": {
        "randomized": "26",
        "analysed": "26"
      },
      "K3 group": {
        "randomized": "26",
        "analysed": "26"
      },
      "C group": {
        "randomized": "26",
        "analysed": "26"
      }
    },
    "depression": [
      {
        "measure": "HADS depression subscale (HAD-D)",
        "day": -1,
        "form": "mean_sd",
        "location": "Table 2",
        "values": {
          "K1 group": {
            "mean": "7.4",
            "sd": "3.2",
            "n": "26"
          },
          "K2 group": {
            "mean": "7.4",
            "sd": "4.9",
            "n": "26"
          },
          "K3 group": {
            "mean": "7.4",
            "sd": "3.7",
            "n": "26"
          },
          "C group": {
            "mean": "7.4",
            "sd": "4.0",
            "n": "26"
          }
        }
      },
      {
        "measure": "HADS depression subscale (HAD-D)",
        "day": 1,
        "form": "mean_sd",
        "location": "Table 2",
        "values": {
          "K1 group": {
            "mean": "10.2",
            "sd": "4.3",
            "n": "26"
          },
          "K2 group": {
            "mean": "10.2",
            "sd": "5.0",
            "n": "26"
          },
          "K3 group": {
            "mean": "6.5",
            "sd": "4.1",
            "n": "26"
          },
          "C group": {
            "mean": "11.2",
            "sd": "3.7",
            "n": "26"
          }
        }
      },
      {
        "measure": "HADS depression subscale (HAD-D)",
        "day": 2,
        "form": "mean_sd",
        "location": "Table 2",
        "values": {
          "K1 group": {
            "mean": "10.3",
            "sd": "4.8",
            "n": "26"
          },
          "K2 group": {
            "mean": "10.3",
            "sd": "5.2",
            "n": "26"
          },
          "K3 group": {
            "mean": "5.7",
            "sd": "3.9",
            "n": "26"
          },
          "C group": {
            "mean": "10.8",
            "sd": "3.7",
            "n": "26"
          }
        }
      },
      {
        "measure": "HADS depression subscale (HAD-D)",
        "day": 3,
        "form": "mean_sd",
        "location": "Table 2",
        "values": {
          "K1 group": {
            "mean": "9.8",
            "sd": "4.7",
            "n": "26"
          },
          "K2 group": {
            "mean": "9.9",
            "sd": "5.4",
            "n": "26"
          },
          "K3 group": {
            "mean": "4.5",
            "sd": "3.3",
            "n": "26"
          },
          "C group": {
            "mean": "10.1",
            "sd": "3.8",
            "n": "26"
          }
        }
      }
    ],
    "pain": [],
    "adverse_events": [
      {
        "window": "emergence",
        "location": "Table 6 (30 min after extubation); Results, Safety Analysis text",
        "values": {
          "K1 group": {
            "agitation": "3",
            "dizziness": "0",
            "visual": "0"
          },
          "K2 group": {
            "agitation": "3",
            "dizziness": "0",
            "visual": "0"
          },
          "K3 group": {
            "agitation": "2",
            "dizziness": "0",
            "visual": "0"
          },
          "C group": {
            "agitation": "1",
            "dizziness": "0",
            "visual": "0"
          }
        }
      }
    ],
    "blinding_check": null,
    "enrollment": {
      "start": "2015-01",
      "end": "2017-10"
    },
    "registration": null,
    "note": "Tables call the control arm 'Control group' (= C group). 26 per group randomized and analysed. HAD-D 'Time_0 h' is the preoperative baseline (text: 'before operation'; all 7.4), so day -1; 24, 48 and 72 h are days 1, 2, 3. VAS only 30 min after extubation, so no pain entries. Adverse events at 30 min after extubation (Table 6): the 'Dysphoria' row is coded as agitation because the text calls it emergence agitation. Not coded: delirium at 30 min (K1 2, K2 1, K3 1, C 0; all 0 at the second assessment) and dysphoria at leaving the operating/recovery room (2, 2, 1, 1). Dizziness and visual zeros are from the text ('No dizziness, nausea, vomiting, diplopia, or other adverse reactions were found 30 min after extubation'), not printed. Hallucination, which the Methods list among recorded events, is not coded: that sentence doesn't name it, and its catch-all 'other adverse reactions' is contradicted by Table 6 ('Disgusting', apparently nausea, 1 (3.8) in K1 and control), so no hallucination count is reported. Enrollment dates from Methods. No registration given.",
    "reason": "The only difference was coder B's hallucination 0 in all four arms at emergence. The Results sentence names dizziness and diplopia (so those zeros stand) but drops hallucination from the Methods' list, and its catch-all 'other adverse reactions' is contradicted by Table 6 on nausea, so the source prints no hallucination count; following 'leave out what it doesn't report', hallucination is left out, as in coder A. Every other value was checked against Tables 2 and 6 and kept."
  },
  {
    "trial": "T045",
    "source": "fulltext",
    "arms": {
      "Esketamine group": {
        "randomized": "75",
        "analysed": "62"
      },
      "Control group (saline; PCIA without esketamine)": {
        "randomized": "75",
        "analysed": "61"
      }
    },
    "depression": [
      {
        "measure": "EPDS",
        "day": -1,
        "form": "median_iqr",
        "location": "Table 2 (Before surgery)",
        "values": {
          "Esketamine group": {
            "median": "7.0",
            "q1": "4.0",
            "q3": "10.0",
            "n": "62"
          },
          "Control group (saline; PCIA without esketamine)": {
            "median": "6.0",
            "q1": "3.0",
            "q3": "9.0",
            "n": "61"
          }
        }
      },
      {
        "measure": "EPDS",
        "day": -1,
        "form": "count",
        "definition": "EPDS score ≥ 13 (PPD risk)",
        "location": "Table 2 (Before surgery)",
        "values": {
          "Esketamine group": {
            "events": "5",
            "n": "62"
          },
          "Control group (saline; PCIA without esketamine)": {
            "events": "6",
            "n": "61"
          }
        }
      },
      {
        "measure": "EPDS",
        "day": 3,
        "form": "median_iqr",
        "location": "Table 2 (3 days postpartum)",
        "values": {
          "Esketamine group": {
            "median": "6.0",
            "q1": "2.0",
            "q3": "8.0",
            "n": "62"
          },
          "Control group (saline; PCIA without esketamine)": {
            "median": "6.0",
            "q1": "3.0",
            "q3": "9.0",
            "n": "61"
          }
        }
      },
      {
        "measure": "EPDS",
        "day": 3,
        "form": "count",
        "definition": "EPDS score ≥ 13 (PPD risk)",
        "location": "Table 2 (3 days postpartum)",
        "values": {
          "Esketamine group": {
            "events": "4",
            "n": "62"
          },
          "Control group (saline; PCIA without esketamine)": {
            "events": "6",
            "n": "61"
          }
        }
      },
      {
        "measure": "EPDS",
        "day": 42,
        "form": "median_iqr",
        "location": "Table 2 (42 days postpartum)",
        "values": {
          "Esketamine group": {
            "median": "5.0",
            "q1": "2.0",
            "q3": "8.0",
            "n": "62"
          },
          "Control group (saline; PCIA without esketamine)": {
            "median": "5.5",
            "q1": "3.0",
            "q3": "8.0",
            "n": "61"
          }
        }
      },
      {
        "measure": "EPDS",
        "day": 42,
        "form": "count",
        "definition": "EPDS score ≥ 13 (PPD risk)",
        "location": "Table 2 (42 days postpartum)",
        "values": {
          "Esketamine group": {
            "events": "5",
            "n": "62"
          },
          "Control group (saline; PCIA without esketamine)": {
            "events": "8",
            "n": "61"
          }
        }
      },
      {
        "measure": "EPDS",
        "day": 90,
        "form": "median_iqr",
        "location": "Table 2 (3 months postpartum)",
        "values": {
          "Esketamine group": {
            "median": "5.0",
            "q1": "1.5",
            "q3": "8.0",
            "n": "60"
          },
          "Control group (saline; PCIA without esketamine)": {
            "median": "5.0",
            "q1": "2.0",
            "q3": "9.0",
            "n": "59"
          }
        }
      },
      {
        "measure": "EPDS",
        "day": 90,
        "form": "count",
        "definition": "EPDS score ≥ 13 (PPD risk)",
        "location": "Table 2 (3 months postpartum)",
        "values": {
          "Esketamine group": {
            "events": "6",
            "n": "60"
          },
          "Control group (saline; PCIA without esketamine)": {
            "events": "7",
            "n": "59"
          }
        }
      },
      {
        "measure": "EPDS",
        "day": 180,
        "form": "median_iqr",
        "location": "Table 2 (6 months postpartum)",
        "values": {
          "Esketamine group": {
            "median": "4.0",
            "q1": "0.0",
            "q3": "8.0",
            "n": "57"
          },
          "Control group (saline; PCIA without esketamine)": {
            "median": "5.5",
            "q1": "2.0",
            "q3": "9.0",
            "n": "57"
          }
        }
      },
      {
        "measure": "EPDS",
        "day": 180,
        "form": "count",
        "definition": "EPDS score ≥ 13 (PPD risk)",
        "location": "Table 2 (6 months postpartum)",
        "values": {
          "Esketamine group": {
            "events": "4",
            "n": "57"
          },
          "Control group (saline; PCIA without esketamine)": {
            "events": "6",
            "n": "57"
          }
        }
      }
    ],
    "pain": [
      {
        "measure": "NRS at rest",
        "day": 1,
        "form": "median_iqr",
        "location": "Table 4 (POD 1)",
        "values": {
          "Esketamine group": {
            "median": "2.0",
            "q1": "1.0",
            "q3": "2.0",
            "n": "62"
          },
          "Control group (saline; PCIA without esketamine)": {
            "median": "2.0",
            "q1": "1.0",
            "q3": "2.0",
            "n": "61"
          }
        }
      },
      {
        "measure": "NRS at rest",
        "day": 2,
        "form": "median_iqr",
        "location": "Table 4 (POD 2)",
        "values": {
          "Esketamine group": {
            "median": "1.0",
            "q1": "0.0",
            "q3": "1.0",
            "n": "62"
          },
          "Control group (saline; PCIA without esketamine)": {
            "median": "1.0",
            "q1": "1.0",
            "q3": "1.0",
            "n": "61"
          }
        }
      },
      {
        "measure": "NRS during coughing",
        "day": 1,
        "form": "median_iqr",
        "location": "Table 4 (POD 1)",
        "values": {
          "Esketamine group": {
            "median": "4.0",
            "q1": "3.0",
            "q3": "4.0",
            "n": "62"
          },
          "Control group (saline; PCIA without esketamine)": {
            "median": "4.0",
            "q1": "4.0",
            "q3": "5.0",
            "n": "61"
          }
        }
      },
      {
        "measure": "NRS during coughing",
        "day": 2,
        "form": "median_iqr",
        "location": "Table 4 (POD 2)",
        "values": {
          "Esketamine group": {
            "median": "3.0",
            "q1": "2.0",
            "q3": "3.0",
            "n": "62"
          },
          "Control group (saline; PCIA without esketamine)": {
            "median": "3.0",
            "q1": "3.0",
            "q3": "4.0",
            "n": "61"
          }
        }
      },
      {
        "measure": "cumulative sufentanil consumption 0-48 h",
        "day": 1,
        "form": "mean_sd",
        "location": "Results 3.3, text (first 24 h)",
        "values": {
          "Esketamine group": {
            "mean": "37.8",
            "sd": "7.4"
          },
          "Control group (saline; PCIA without esketamine)": {
            "mean": "47.3",
            "sd": "8.3"
          }
        }
      },
      {
        "measure": "cumulative sufentanil consumption 0-48 h",
        "day": 2,
        "form": "mean_sd",
        "location": "Results 3.3, text (48 h)",
        "values": {
          "Esketamine group": {
            "mean": "74.5",
            "sd": "12.3"
          },
          "Control group (saline; PCIA without esketamine)": {
            "mean": "86.4",
            "sd": "13.5"
          }
        }
      }
    ],
    "adverse_events": [
      {
        "window": "intraoperative",
        "location": "Table 4",
        "values": {
          "Esketamine group": {
            "hallucination": "3",
            "nightmare": "1",
            "dizziness": "10"
          },
          "Control group (saline; PCIA without esketamine)": {
            "hallucination": "0",
            "nightmare": "0",
            "dizziness": "2"
          }
        }
      },
      {
        "window": "postoperative",
        "location": "Table 4",
        "values": {
          "Esketamine group": {
            "hallucination": "2",
            "nightmare": "1",
            "dizziness": "6"
          },
          "Control group (saline; PCIA without esketamine)": {
            "hallucination": "0",
            "nightmare": "0",
            "dizziness": "4"
          }
        }
      }
    ],
    "blinding_check": null,
    "enrollment": {
      "start": "2021-05",
      "end": "2021-12"
    },
    "registration": {
      "number": "ChiCTR2100046049",
      "date": null
    },
    "note": "150 randomized; 75 per arm from the sample-size section ('we enrolled 75 patients in each group'), consistent with exclusions of 13 (6 withdrew consent, 7 lost) and 14 (8 withdrew, 6 lost); 62 and 61 analysed. The source calls the control arm 'control group' (saline infusion; PCIA without esketamine). EPDS baseline was a face-to-face interview one day before surgery; follow-up online at 3 days, 42 days, 3 months and 6 months (entered as days 3, 42, 90, 180); the 3- and 6-month n come from Table 2's subheadings, the others from its header. Methods state the PPD cut-off as 'EPDS score > 12'; Table 2 prints '≥ 13'. EPDS area under the curve 130.2 ± 115.9 vs 152.2 ± 126.6 not entered; EPDS-3A anxiety not entered. Sufentanil 0-24 h and 0-48 h from the Results text (no n); 0-12, 12-24 and 24-48 h only in Figure 2. Adverse events from Table 4; the Results text calls intraoperative dizziness 'significantly lower in the esketamine group' while printing 16.1 % vs 3.3 %, which matches Table 4's 10 (esketamine) vs 2 (control), so the table is taken. Nausea, vomiting and pruritus not coded. Enrollment period from Methods (trial 'conducted ... between May 2021 and December 2021'); the Results give no dates.",
    "reason": "The coders differed only in writing a missing n for the 0-24 h and 0-48 h sufentanil means (coder A n: null, coder B no n). The Results text prints them without an n and Figure 2's caption gives none, so n is left out, since the codebook records n only if given (coder B's form). All other values were checked against Tables 2 and 4 and agree; Table 4's adverse events are kept over the text's reversed statement on intraoperative dizziness."
  },
  {
    "trial": "T071",
    "source": "fulltext",
    "arms": {
      "Ketamine": {
        "randomized": "16",
        "analysed": null
      },
      "Normal saline placebo": {
        "randomized": "16",
        "analysed": null
      }
    },
    "depression": [
      {
        "measure": "MADRS",
        "day": -1,
        "form": "median_iqr",
        "location": "Table 1 (Preoperative MADRS); same in Results text",
        "values": {
          "Ketamine": {
            "median": "14.5",
            "q1": "9",
            "q3": "21",
            "n": "16"
          },
          "Normal saline placebo": {
            "median": "12.5",
            "q1": "6",
            "q3": "23.5",
            "n": "16"
          }
        }
      },
      {
        "measure": "MADRS",
        "day": 4,
        "form": "median_iqr",
        "location": "Results, Collection of clinical outcomes, text (post-infusion day 4)",
        "values": {
          "Ketamine": {
            "median": "4",
            "q1": "2",
            "q3": "16"
          },
          "Normal saline placebo": {
            "median": "6",
            "q1": "3.5",
            "q3": "12"
          }
        }
      }
    ],
    "pain": [
      {
        "measure": "total opioid dose (oral morphine equivalents) to 07:00 post-infusion day 2",
        "day": 2,
        "form": "median_iqr",
        "location": "Results, Collection of clinical outcomes, text",
        "values": {
          "Ketamine": {
            "median": "78.2",
            "q1": "52.5",
            "q3": "219"
          },
          "Normal saline placebo": {
            "median": "118",
            "q1": "32.2",
            "q3": "179.5"
          }
        }
      }
    ],
    "adverse_events": [
      {
        "window": "postoperative",
        "location": "Table 2 (during the study infusion)",
        "values": {
          "Ketamine": {
            "dizziness": "5",
            "visual": "2",
            "agitation": "0"
          },
          "Normal saline placebo": {
            "dizziness": "2",
            "visual": "1",
            "agitation": "1"
          }
        }
      }
    ],
    "blinding_check": {
      "who": "participants",
      "when": "1 day after the infusion",
      "location": "Results, Study medication administration",
      "values": {
        "Ketamine": {
          "correct": "7",
          "n": "16"
        },
        "Normal saline placebo": {
          "correct": "7",
          "n": "16"
        }
      }
    },
    "enrollment": {
      "start": "2022-05-05",
      "end": "2023-02-21"
    },
    "registration": {
      "number": "NCT05233566",
      "date": "2022-02-10"
    },
    "note": "Feasibility trial; the study drug started after extubation, so days are the source's post-infusion days (infusion delayed to POD 1 for three control participants and to POD 2 for one ketamine participant). 16 per arm randomized (Table 1 N); no per-arm analysed n (MADRS completed at 170 of 192 planned assessments). MADRS on days 1, 2, 7 and 14 appears only in Figure 4 (box plots); the day-4 medians (IQR) come from the Results text, with no n. Median regression difference in change from baseline to day 4, adjusted for baseline: −1.00 (95% CI −3.23 to 1.73); post hoc subgroup with baseline MADRS >6: −1.76 (−3.63 to 2.77). Pain scores appear only in supplementary figures. Opioid: 'cumulative postoperative opioid exposure between the start of the study medication infusion and 07:00 am on post-infusion day 2', printed as 78.2 (IQR 52.5–219) vs 118 (IQR 32.2–179.5) oral morphine milligram equivalents; the central value is read as a median because an IQR is given; entered as day 2 per the design. Adverse events from Table 2, during the infusion (3 control participants refused or could not be interviewed, so control rows total 13): Dizziness 5 (31) vs 2 (15); Seeing double 2 (12) vs 1 (8) as visual; RASS '1 (Restless)' 0 (0) vs 1 (8) as agitation. Not coded because a count would need summing across scale levels: BPRS hallucinatory behaviour, ketamine 16 (100) no symptoms with 0 (0) at scores 2 and 3, control 11 (85) no symptoms, 1 (8) at score 2 and 1 (8) at score 3; CADSS-6, ketamine 0: 9 (56), 1: 3 (19), 2: 1 (6), 3: 1 (6), 4: 2 (12), 6: 0 (0), control 0: 11 (85), 4: 1 (8), 6: 1 (8); BPRS conceptual disorganisation, ketamine 1 (6) at score 3, control 2 (15) at score 2. Blinding: 'seven out of 16 participants in the ketamine group and seven out of 16 participants in the control group correctly guessed which treatment they received'. One control participant died on postoperative day 13. Enrollment: participants included between 5 May 2022 and 21 February 2023 (recruitment 11 April 2022 to 17 February 2023). Registration date is the 'first posted' date.",
    "reason": "Same kind of difference: coder A wrote n: null for the day-4 MADRS medians (IQR) and the opioid dose, coder B left n out. Both come from Results text that prints no n (MADRS was done at 170 of 192 planned time points, with no per-arm count), so n is left out. Baseline MADRS (Table 1), adverse events (Table 2), the blinding guesses, dates and registration were checked against the source and kept."
  },
  {
    "trial": "T101",
    "source": "fulltext",
    "arms": {
      "Esketamine group": {
        "randomized": "90",
        "analysed": "86"
      },
      "Placebo group": {
        "randomized": "90",
        "analysed": "87"
      }
    },
    "depression": [
      {
        "measure": "PHQ-8",
        "day": -1,
        "form": "median_iqr",
        "location": "Table 1 (Preoperative status, PHQ-8 score)",
        "values": {
          "Esketamine group": {
            "median": "6",
            "q1": "5",
            "q3": "9",
            "n": "86"
          },
          "Placebo group": {
            "median": "7.0",
            "q1": "4",
            "q3": "10",
            "n": "87"
          }
        }
      },
      {
        "measure": "PHQ-8",
        "day": 3,
        "form": "median_iqr",
        "location": "Table 3 (PHQ-8 score POD3)",
        "values": {
          "Esketamine group": {
            "median": "5",
            "q1": "3",
            "q3": "8",
            "n": "86"
          },
          "Placebo group": {
            "median": "5",
            "q1": "3",
            "q3": "8",
            "n": "87"
          }
        }
      },
      {
        "measure": "PHQ-8",
        "day": 30,
        "form": "median_iqr",
        "location": "Table 3 (PHQ-8 score POD30)",
        "values": {
          "Esketamine group": {
            "median": "5",
            "q1": "2",
            "q3": "8"
          },
          "Placebo group": {
            "median": "6",
            "q1": "3",
            "q3": "10"
          }
        }
      }
    ],
    "pain": [
      {
        "measure": "NRS pain",
        "day": 1,
        "form": "median_iqr",
        "location": "Table 3 (NRS score at rest POD1)",
        "values": {
          "Esketamine group": {
            "median": "1",
            "q1": "0",
            "q3": "2"
          },
          "Placebo group": {
            "median": "1",
            "q1": "0",
            "q3": "2"
          }
        }
      },
      {
        "measure": "NRS pain",
        "day": 2,
        "form": "median_iqr",
        "location": "Table 3 (NRS score at rest POD2)",
        "values": {
          "Esketamine group": {
            "median": "0",
            "q1": "0",
            "q3": "1"
          },
          "Placebo group": {
            "median": "0",
            "q1": "0",
            "q3": "1"
          }
        }
      }
    ],
    "adverse_events": [],
    "blinding_check": null,
    "enrollment": {
      "start": "2024-08-05",
      "end": "2025-06-30"
    },
    "registration": {
      "number": "NCT06530706",
      "date": "2024-07-31"
    },
    "note": "180 randomized (90 and 90); 88 per arm received the allocated intervention; 86 and 87 analysed (primary endpoint data). PHQ-8 baseline from Table 1 'Preoperative status' (collected after consent, before surgery). Table 3 adjusted mean differences (ANCOVA): PHQ-8 POD3 0 (−1 to 1), POD30 −2 (−3 to −1). POD30 n is left out: Table 3's header says n=86 and n=87, but HAMA ≤ 7 at POD30 has denominators 84 and 85. The design lists one pain measure, 'NRS pain'; the source reports NRS at rest and at cough (Table 3, exploratory): rest is entered as 'NRS pain'; cough is not a measure the design lists, so it is not entered (Table 3, esketamine vs placebo, median [IQR]: POD1 3 [1, 4] vs 2 [1, 4]; POD2 2 [1, 3] vs 2 [1, 3]). The pain n is left out because Table 4's POD1 and POD2 nausea denominators are 84 and 85 in the esketamine group. NRS after extubation 0 [0, 2] in both groups (day 0) not entered. No psychotomimetic adverse events are reported: Table 4 covers hypotension, vasopressors, hypertension, antihypertensives, nausea and vomiting, and 'No serious adverse events were reported in either group'. Enrollment from the Results ('from 5 Aug, 2024 to 30 Jun, 2025').",
    "reason": "Coder A wrote n: null where coder B left n out (PHQ-8 at POD30, NRS at POD1 and POD2). Table 3's header says 86 and 87, but its POD30 HAMA rows use 84 and 85 and Table 4's POD1-2 rows use 84 and 85 for esketamine, so the source gives no n for these and n is left out (coder B). Both coders also entered 'NRS score at cough', which the design doesn't list; measure names follow the design, so those two entries are removed and their values kept in the note, with NRS at rest staying as the design's 'NRS pain'."
  },
  {
    "trial": "T052",
    "source": "fulltext",
    "arms": {
      "Group E": {
        "randomized": "60",
        "analysed": "58"
      },
      "Group C": {
        "randomized": "60",
        "analysed": "57"
      }
    },
    "depression": [
      {
        "measure": "DSM-IV clinical interview for PPD",
        "day": 7,
        "form": "count",
        "definition": "PPD: EPDS > 9 screen, then DSM-IV clinical interview",
        "location": "Table 2",
        "values": {
          "Group E": {
            "events": "2",
            "n": "58"
          },
          "Group C": {
            "events": "9",
            "n": "57"
          }
        }
      },
      {
        "measure": "DSM-IV clinical interview for PPD",
        "day": 42,
        "form": "count",
        "definition": "PPD: EPDS > 9 screen, then DSM-IV clinical interview",
        "location": "Table 2",
        "values": {
          "Group E": {
            "events": "3",
            "n": "58"
          },
          "Group C": {
            "events": "11",
            "n": "57"
          }
        }
      }
    ],
    "pain": [],
    "adverse_events": [
      {
        "window": "postoperative",
        "time": "within 48 h after the operation",
        "location": "Table 2",
        "n": {
          "Group E": "58",
          "Group C": "57"
        },
        "terms": {
          "nightmare": "Nightmares"
        },
        "values": {
          "Group E": {
            "nightmare": "2"
          },
          "Group C": {
            "nightmare": "3"
          }
        }
      }
    ],
    "blinding_check": null,
    "enrollment": {
      "start": "2022-04-01",
      "end": "2022-11-30"
    },
    "registration": {
      "number": "ChiCTR2200060387",
      "date": "2022-05-30"
    },
    "note": "Table 2 'PPD' counts use the paper's two-step definition (EPDS > 9 screen, then a DSM-IV clinical interview by physicians blind to group), so they are entered under 'DSM-IV clinical interview for PPD'; the number screening positive on the EPDS is not reported separately, so 'EPDS screen (>9)' has no entry. Results text repeats the percentages (1 week 15.8% vs 3.4%; 6 weeks 19.3% vs 5.2%, C vs E). Randomized 60 per group (Methods 2.3, 'with 60 cases in each group'). Of the Table 2 adverse reactions (within 48 h), only nightmares map to a category (drowsiness is not dizziness). Enrollment dates come from Methods 2.2 and 2.5; the Results don't restate them. Registration (30 May 2022) is after enrollment began (1 April 2022).",
    "reason": "The coders agree on every number (Table 2 PPD 2/58 vs 9/57 at 1 week and 3/58 vs 11/57 at 6 weeks; nightmares 2 vs 3 within 48 h); they differed only in where the count's definition sits. It describes the whole entry (PPD by an EPDS > 9 screen and then a DSM-IV interview, participants with depression rather than responders), so it is kept once at the entry level, as in coder B, rather than repeated inside each arm."
  }
]